Cibus, Inc. (CBUS) vs MaxCyte, Inc. (MXCT)
A side-by-side comparison of Cibus, Inc. and MaxCyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CBUS
Cibus, Inc.
$1.61HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
MXCT
MaxCyte, Inc.
$1.07HealthcareDelayed quote: Oct 6, 2026, 11:27 AM EDT
Total return — CBUS vs MXCT
growth of $100 · dividends reinvested · last 5yCBUS -99.1% (-61.1%/yr)MXCT -93.6% (-42.4%/yr)MXCT compounded faster over this window
Log scale — wide-divergence pair
CBUS MXCT
CBUS vs MXCT: by the numbers
- •CBUS is the larger company ($123M vs $114M market cap).
- •Both run net losses; MXCT's is the smaller (-114.77% vs -2258.89% net margin).
- •MXCT grew revenue faster over the past five years (1.46% vs -34.28% CAGR).
Metrics side by side
Valuation
| Metric | CBUS | MXCT |
|---|---|---|
| P/S ratio | 28.27 | 3.67 |
| P/B ratio | 8.30 | 0.72 |
Profitability
| Metric | CBUS | MXCT |
|---|---|---|
| Gross margin | -62.76% | 79.43% |
| Operating margin | -1853.92% | -137.12% |
| Net margin | -2258.89% | -114.77% |
| ROE | -663.38% | -22.45% |
| ROIC | -17.99% | -19.83% |
Growth (annualized)
| Metric | CBUS | MXCT |
|---|---|---|
| Revenue CAGR (5Y) | -34.28% | 1.46% |
| Total return CAGR (5Y) | -59.70% | -37.32% |
Frequently asked
- Which has grown faster, CBUS or MXCT?
- Over the past five years, MXCT grew revenue faster — CBUS at a -34.28% CAGR versus MXCT at 1.46%.
- How have CBUS and MXCT total returns compared?
- Over the past 5 years, CBUS delivered -59.70% and MXCT delivered -37.32% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.